New treatment for HER2-positive breast cancer rolled out across the country
PHESGO is a fixed-dose combination of pertuzumab with trastuzumab (previously only available as separate IV infusions) that takes as little as 5 minutes to prepare and administer, thus reducing the amount of time spent in hospital.
Source:
NHS England
SPS commentary:
The injection will be offered to eligible people with HER2-positive breast cancer, and can be given alongside chemotherapy or on its own. Care providers were told they could begin offering the treatment in February and the agreement between the health service, NICE and the manufacturer means it comes at no extra cost to the NHS. More than 3,600 new patients each year will benefit from the treatment, as well as others who will switch from the treatment they are on to the single injection.